Clinical trial
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or…
NCT00057720 · Telik, Industry · Completed
Key facts
| NCT number | NCT00057720 |
|---|---|
| Title | TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer |
| Official title | Phase 3 Randomized Study of TLK286 (Telcyta) Versus Doxil/Caelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-1 (Assessment of Survival In Solid Tumors-1)] |
| Lead sponsor | Telik, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms |
| Intervention type | Drug |
| Interventions | TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection |
| Enrollment | 440 |
| Start date | Jun 1, 2003 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Apr 8, 2003 |
| Last update posted | Jul 25, 2011 |
| Countries | Argentina, Belgium, Brazil, Chile, Czechia, Germany, Hungary, Ireland, Netherlands, South Africa, Spain, United Kingdom and 1 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: